Daily Stock Setups

BiomedReports: News and FDA Updates for Clinical Data (NASDAQ:CLDA), Delcath (Nasdaq:DCTH), CytRx (NASDAQ:CYTR)

Posted on: Thu, 19 Nov 2009 10:50:00 EST

Symbols: CYTR, CLDA, DCTH

Are you looking to increase your ETF knowledge?

Pasadena, CA, Nov 19, 2009 (M2 PRESSWIRE via COMTEX) --
DCTH | Quote | Chart | News | PowerRating -- BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.

A complete list of all headlines and biomedical stock developments can be found on BioMedReports.Com

On 18/11/09, Clinical Data, Inc. (NASDAQ: CLDA | Quote | Chart | News | PowerRating) announced it has enrolled the first patient in its initial Phase III trial of Stedivaze, a potential best-in-class vasodilator for use in cardiac stress testing.

On 18/11/09, Delcath Systems, Inc. (Nasdaq:DCTH) announced the closing of its public offering of 9,775,000 shares of common stock priced to the public at $3.60 per share.

On 18/11/09, CytRx Corporation (NASDAQ: CYTR | Quote | Chart | News | PowerRating), a biopharmaceutical company, announced plans to initiate an open-label, multinational Phase 2 clinical trial with its doxorubicin prodrug INNO-206 as a second-line treatment in patients with advanced gastric (stomach) cancer.

Biotech investors interested in seeing more details about these stories and accessing the complete database of clinical trials and upcoming FDA decisions can access that information here:

http://biomedreports.com/fda-calendar/fda-calendar.html

Disclosure: No positions.

About BiomedReports.Com

BioMedReports.com is a news portal covering the biomedical news and financial sector. It features its own blog, discussion forum, stock research reports, news feeds, videos, press release capability, stock commentaries, and other unique content - including FDA and Clinical Trial Calendars plus a database that includes about 1,000 stocks and exchange-traded funds from the healthcare sector which are organized into various new healthcare stock indexes.

For more biomedical sector and investment news, go to www.BioMedReports.com

Certain sections of this report contain forward-looking statements that are based on our reporters' expectations, estimates, projections and assumptions. Words such as "expects" "anticipates" "plans" "believes" "scheduled" "estimates" and variations of these words and similar expressions are intended to identify forward-looking statements, which include but are not limited to projections of revenues, earnings, segment performance, cash flows, contract awards, FDA announcements, trial and drug approvals, and company stability. Forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what is forecast in forward-looking statements due to a variety of factors including but not limited to the status or outcome of legal and/or regulatory proceedings.

All forward-looking statements speak only as of the date of this report or, in the case of any document incorporated by reference, the date of that document. All subsequent written and oral forward-looking statements attributable to the company or any person acting on the company's behalf are qualified by the cautionary statements in this section. BioMedReports.Com does not undertake any obligation to update or publicly release any revisions to forward-looking statements to reflect events, circumstances or changes in expectations after the date of this report.

CONTACT: M. Davila, Editor, BioMedReports.Com
e-mail: support@biomedreports.com
Tel: +1 323 472 4480
Fax: +1 888 210 3556

((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

For full details on Cytrx Corporation (CYTR) CYTR. Cytrx Corporation (CYTR) has Short Term PowerRatings at TradingMarkets. Details on Cytrx Corporation (CYTR) Short Term PowerRatings is available at This Link.

For full details on Clinical Data Inc (CLDA) CLDA. Clinical Data Inc (CLDA) has Short Term PowerRatings at TradingMarkets. Details on Clinical Data Inc (CLDA) Short Term PowerRatings is available at This Link.

For full details on Delcath Systems Inc (DCTH) DCTH. Delcath Systems Inc (DCTH) has Short Term PowerRatings at TradingMarkets. Details on Delcath Systems Inc (DCTH) Short Term PowerRatings is available at This Link.

More News: Market Updates | Stock Alerts | All Trading News

Disclaimer:

The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.

It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.

HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.

The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302

All analyst commentary provided on TradingMarkets.com is provided for educational purposes only. The analysts and employees or affiliates of TradingMarkets.com may hold positions in the stocks or industries discussed here. This information is NOT a recommendation or solicitation to buy or sell any securities. Your use of this and all information contained on TradingMarkets.com is governed by the Terms and Conditions of Use. Please click the link to view those terms. Follow this link to read our Editorial Policy.